Literature DB >> 14529348

Modified envelope glycoproteins to retarget retroviral vectors.

Catherine Haynes1, Otto Erlwein, Barbara S Schnierle.   

Abstract

A conceptual breakthrough in gene therapy would be gene transfer vector that could be systemically applied, allowing targeted gene transfer into a predetermined cell type. The host range of a retroviral vector is determined by the interaction of the viral envelope glycoprotein (Env) and the retrovirus receptor on the surface of the host cell. In this review, we describe the current efforts to engineer targeted envelope glycoproteins, which can be incorporated into retroviral particles and are capable of delivering genes in a highly specific manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529348     DOI: 10.2174/1566523034578267

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  4 in total

1.  Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.

Authors:  Christian Metzl; Daniela Mischek; Brian Salmons; Walter H Günzburg; Matthias Renner; Daniel Portsmouth
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 2.  Selective gene silencing by viral delivery of short hairpin RNA.

Authors:  Katja Sliva; Barbara S Schnierle
Journal:  Virol J       Date:  2010-09-21       Impact factor: 4.099

3.  Murine leukemia virus (MLV) replication monitored with fluorescent proteins.

Authors:  Katja Sliva; Otto Erlwein; Alexandra Bittner; Barbara S Schnierle
Journal:  Virol J       Date:  2004-12-20       Impact factor: 4.099

Review 4.  Engineering targeted viral vectors for gene therapy.

Authors:  Reinhard Waehler; Stephen J Russell; David T Curiel
Journal:  Nat Rev Genet       Date:  2007-07-03       Impact factor: 53.242

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.